# Kestra Medical Technologies Ltd. (KMTS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $25.54, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Kestra Medical Technologies Ltd. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 15.7×**. Each dollar of revenue is priced at 15.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.8%** (5-yr avg -13.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 51.4%**. Kestra Medical Technologies Ltd. keeps 51.4% of revenue after the direct cost of what it sells.
- **Operating margin: -141.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -138.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -50.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -52.5%**. Return on all capital, debt included, is -52.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -36.7%**. Each dollar of assets produces -36.7% of profit.

## Growth
- **Revenue growth (1 yr): 59.0%**. Revenue grew 59.0% over the last year.
- **EPS growth (1 yr): 52.6%**. Earnings per share rose 52.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.16**. Debt is 0.16 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.5×**. It would take 0.5 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 9.13**. A Z-score of 9.13 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Kestra Medical Technologies Ltd. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Kestra Medical Technologies Ltd.; the consensus is strong_buy, with an average price target of $30.00 (+17% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 54.7%** (YTD -3.7%, 3-mo 31.6%). The shares are up 54.7% over twelve months including dividends.
- **From 52-week high: -14.9%** (47.3% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 1.72** (volatility 64%). Beta of 1.72 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KMTS · Page: https://foliofundamentals.com/stocks/kmts

Not investment advice.